In a shocking reversal, Biogen on Tuesday said that it would resurrect an Alzheimer’s drug that the company previously said had failed and will ask the Food and Drug Administration to approve it.

The company said a “new analysis of a larger dataset” showed that the drug, aducanumab, reduced clinical decline in patients with early Alzheimer’s disease on multiple measures of the drug’s effectiveness. That directly contradicts a decision in March to halt studies of the therapy based on the recommendations of an independent monitoring board that was charged with protecting patients in the study.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I have see too much suffering from this disease to last me a life time. 20 more years? Really? I don’t want to hear or read how all the research and trails have done nothing but FAILED. Praying that a successful trail is reached before 20 years.

  • My wife has Alzheimer’s and we are interested in this drug. Please keep me up to date and consider her for one of your trials. Thanks

  • Again I was sent link to new trial for Alzheimer’s treatment but no deal for me since only for previous patients. Why in God’s name do you put this out and get ones hopes up THEN quash them with Governmental double speak. Stop putting this out for false for old people who will be dead or better yet won’t remember their names when DRUG approved. . 🔺 Then drug only slows down disease. Yeh that’s better than nothing but not by much. This isn’t first time I have been given a smidgeon of false hope by some moron in the advertising department. Hell I am just rambling. John Gowan. 57 mistletoe ct. lake Jackson Texas. 77566. 9792996699.

    L

  • For those asking about “how do I enroll in the trial?” Your best bet is to have your doctor submit you for application into the trial.

    Beyond that you can go to the following link and search for the active trials section, find the trial you are looking for and find contact information.

    https://clinicaltrials.gov/ct2/results?term=&recr=Recruiting&rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=biogen&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=

    For Biogen the contact info is here.

    Contact: US Biogen Clinical Trial Center 866-633-4636 clinicaltrials@biogen.com
    Contact: Global Biogen Clinical Trial Center clinicaltrials@biogen.com

  • Fantastic! This drug can be the light to Alzheimer’s patients recovery! Congratulations 👍👏👏👏😍 How do I get my aunt enrolled in this trial ? Thank you ‼️

  • Are there any clinical trials still open for this? If so, please provide information on how/where to participate.

  • This is contrary to current research on beta amyloid, considered a dead end. Drug companies bet the bank but it did NOT succeed for any of the beta amyloid drugs. Funny how trump’s FDA is ignoring all the research so company can recoup some loses. Buyer be very beware. Google recent research on beta amyloid and drug treatments.

    • I agree. Every statistician, including the FDA’s, knows that once you start cherry picking the data you can find the result you are looking for purely by chance. Either way, a 23% reduction in the rate of decline is hardly stunning – especially if it is accompanied by side effects. Patients are having their hopes raised when what we need is a new approach to this disease.

    • Actually I have the answer (I didn’t know that). The APP gene in Downs Syndrome produces a specific protein called amyloid precursor protein (APP). Too much APP protein leads to a buildup of protein clumps called beta-amyloid plaques in the brain.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy